Spots Global Cancer Trial Database for Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Official Title: A Multicenter Phase 1/2a, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors
Study ID: NCT04106492
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope, Duarte, California, United States
Stanford Cancer Center, Palo Alto, California, United States
Sarcoma Oncology Center, Santa Monica, California, United States
Washington University in St. Louis, Saint Louis, Missouri, United States
Oregon Health & Science University, Portland, Oregon, United States
MD Anderson Cancer Center, Houston, Texas, United States
University of Washington, Seattle, Washington, United States
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Royal North Shore Hospital, Sydney, New South Wales, Australia
Cancer Research Institute, Adelaide, South Australia, Australia
Contact Details
Name: Jim Williams, MD
Affiliation: Shasqi, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
